It wasn’t so long ago that I did a post explaining why after following the company for years, I finally bought a small amount of stock in the stem cell biotech, Advanced Cell Technology (ACT; symbol ACTC). In part it was motivated by my enthusiasm to see them publishing a paper, a very preliminary paper, on their human ES cell-based clinical trials for macular degeneration. However, being more of a scientist than a stock trader, I found myself fairly quickly having second thoughts, particularly ...Read More
The post Why Lanza and I sold ACT stock appeared first on The Niche.